Details for New Drug Application (NDA): 206813
✉ Email this page to a colleague
The generic ingredient in POTASSIUM CITRATE is potassium citrate. There are two hundred and forty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the potassium citrate profile page.
Summary for 206813
Tradename: | POTASSIUM CITRATE |
Applicant: | Strides Pharma |
Ingredient: | potassium citrate |
Patents: | 0 |
Pharmacology for NDA: 206813
Mechanism of Action | Acidifying Activity Calcium Chelating Activity |
Physiological Effect | Decreased Coagulation Factor Activity |
Medical Subject Heading (MeSH) Categories for 206813
Suppliers and Packaging for NDA: 206813
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
POTASSIUM CITRATE | potassium citrate | TABLET, EXTENDED RELEASE;ORAL | 206813 | ANDA | Strides Pharma Inc. | 42543-406 | 42543-406-01 | 100 TABLET in 1 BOTTLE (42543-406-01) |
POTASSIUM CITRATE | potassium citrate | TABLET, EXTENDED RELEASE;ORAL | 206813 | ANDA | Strides Pharma Inc. | 42543-407 | 42543-407-01 | 100 TABLET in 1 BOTTLE (42543-407-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 5MEQ | ||||
Approval Date: | Sep 11, 2017 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 10MEQ | ||||
Approval Date: | Sep 11, 2017 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 15MEQ | ||||
Approval Date: | Sep 11, 2017 | TE: | AB | RLD: | No |
Complete Access Available with Subscription